Huge news! The #SELECT trial presented at #AHA23 is a game changer. Among adults with CVD and overweight/ #obesity but without diabetes, #semaglutide 2.4mg/wk reduced MACE by 20%, HF by 18%, and all-cause mortality by 19%! 👏👏👏
These results with semaglutide were additive to background standard of care for CVD. MACE reduction with sema was consistent across subgroups. Sema conferred 9% reduction in body weight, significant reduction in BP, CRP, TG & ⬇️⬇️ in progression to diabetes or prediabetes #AHA23
Loading suggestions...